4.7 Article

A pathway in quiescent cells that controls p27(Kip1) stability, subcellular localization, and tumor suppression

Journal

GENES & DEVELOPMENT
Volume 20, Issue 1, Pages 47-64

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.1384406

Keywords

p27(Kip1); cyclin; CDK; tumor suppressor; tumorigenesis; Ras; lung cancer

Funding

  1. NATIONAL CANCER INSTITUTE [R01CA099517] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011045] Funding Source: NIH RePORTER
  3. NCI NIH HHS [R01 CA099517, T32 CA8046] Funding Source: Medline
  4. NIEHS NIH HHS [U01 ES011045, U01 ES11045] Funding Source: Medline

Ask authors/readers for more resources

We have created two knock-in mouse models to study the mechanisms that regulate p27 in normal cells and cause misregulation of p27 in tumors: p27(S10A), in which Ser10 is mutated to Ala; and p27(CK), in which point mutations abrogate the ability of p27 to bind cyclins and CDKs. These two mutant alleles identify steps in a pathway that controls the proteasomal degradation of p27 uniquely in quiescent cells: Dephosphorylation off p27 on Ser10 inhibits p27 nuclear export and promotes its assembly into cyclin-CDK complexes, which is, in turn, necessary for p27 turnover. We further show that Ras-dependent lung tumorigenesis is associated with increased phosphorylation on Ser10 and cytoplasmic mislocalization of p27. Indeed, we find that p27(S10A) is refractory to Ras-induced cytoplasmic translocation and that p27(S10A) mice are tumor resistant. Thus, phosphorylation of p27 on Ser10 is an important event in the regulation of the tumor suppressor function of p27.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available